Clinico-pathological factors predicting pathological response in early triple-negative breast cancer
Clara Helal(Institut Curie), Luc Cabel(Université de Versailles Saint-Quentin-en-Yvelines), Emanuela Romano(Université Paris Sciences et Lettres), Matthieu Carton(Institut Curie), Paul Cottu(Université Paris Sciences et Lettres), Enora Laas(Institut Curie), Anne Vincent‐Salomon(Université Paris Sciences et Lettres), Ivan Bièche(Centre National de la Recherche Scientifique), Claire Bonneau(Inserm), Romain‐David Seban(Institut Curie), Nicolas Kiavué(Institut Curie), Diana Bello-Roufai(Hôpital René Huguenin), Lounes Djerroudi(Memorial Sloan Kettering Cancer Center), Delphine Loirat(Institut Curie), Maxime Jin(Inserm), Toulsie Ramtohul(Université Paris Sciences et Lettres), Florence Lerebours(Institut Curie), François‐Clément Bidard(Inserm)
Cited by 24
Related Papers
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
|Cancer Cell|2018|1.7k
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
|Journal of Clinical Oncology|2022|676
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
|Annals of Oncology|2024|343
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
|Annals of Oncology|2021|294
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282